Vaxart

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.

Over 90% of norovirus' total annual cost is due to sporadic spread in the community. Over 90% of norovirus' total annual cost is due to sporadic spread in the community.

Norovirus Gastroenteritis Costs an Estimated $10.6 Billion Each Year in the United States

Moderna

Both Moderna and Vaxart are expecting data readouts that will send the stocks skyrocketing -- if the news is positive.

These 2 Coronavirus Stocks Could Soar in the Second Half of 2020

Investors are growing increasingly bullish on the coronavirus vaccine maker's growth prospects.

Why Vaxart Stock Soared 40% Today

Vaxart Inc (NASDAQ: VXRT) shares are trading higher on Monday after B Riley FBR initiated coverage on the company's stock with a Buy rating and announced a $22 price target.

Why Vaxart's Stock Is Trading Higher Today

RA Capital Management to own approximately 9.99% of the Company’s outstanding common stock RA Capital Management to own approximately 9.99% of the Company’s outstanding common stock

Vaxart Raises Approximately $90M in Gross Proceeds Through its At-The-Market-Facility

As a small and scrappy competitor in the COVID-19 vaccine race, Vaxart is a lucrative opportunity for investors of all stripes.

Everything You Need to Know About Vaxart and Its Potential Coronavirus Vaccine

Both companies are developing new types of vaccines. The risk is high -- but so is potential for share performance.

Coronavirus Vaccine Race: Moderna or Vaxart?

Altimmune

Both of these small-cap vaccine stocks are up big in 2020.

Better Coronavirus Stock: Altimmune vs. Vaxart

VBI Vaccines

There's more to these small biotechs than just their coronavirus vaccine programs.

Better Coronavirus Stock: VBI Vaccines or Vaxart?

Vaxart's Technology Could Be A COVID-19 Game Changer

Vaxart is a small cap, clinical-stage biotech company that develops oral tablet vaccines for infectious diseases.

Vaxart: A Speculative Buy For Its Oral COVID-19 Vaccine

Thanks to its innovative vaccine technology platform and recently fast-tracked COVID-19 vaccine candidate, Vaxart is likely a millionaire-maker stock.

Could Investing in Vaxart Make You a Millionaire?

Vaxart's (VXRT) oral COVID-19 vaccine candidate is picked for a non-human primate challenge study as part of the Operation Warp Speed initiative to rapidly develop a vaccine against SARS-CoV-2.

Vaxart's Oral Coronavirus Vaccine Candidate Gets Chosen by OWS

Momentum from last week's big news continues.

Why Vaxart Shares Are Vaulting Higher Again

Inovio Pharmaceuticals

After an unbelievable week, Investors want to know if these drugmakers have what it takes to keep climbing.

2 Biotech Stocks That Rocketed Higher Last Week

A company's vaccine manufacturing capabilities can make a world of difference.

Better Coronavirus Stock:  VBI Vaccines or  Vaxart?

Vaxart’s aggressive moves to scale up its vaccine-manufacturing capabilities bode well for the company’s future.

Smart Investors Might Consider Buying This Coronavirus Stock That Just Popped 96%

Vaxart stock rocketed Friday after the federal government selected its coronavirus vaccine for the Operation Warp Speed program. Translate Bio stock, however, fell on a public offering.

Covid Report: Tiny Biotech Stock Catapults 28% As Feds Eye Its Vaccine

The coronavirus vaccine maker will participate in a government-funded study.

Why Vaxart Stock Skyrocketed Today

Shares of oral vaccine maker Vaxart Inc (NASDAQ: VXRT) are on a strong two-day run after two announcements tied to coronavirus vaccine development.

Vaxart Rallies On Double Dose Of Positive Coronavirus Vaccine Developments

Vaxart Inc. VXRT, +96.23% said Friday its oral COVID-19 vaccine has been selected to take part in a non-human primate challenge study funded by the U.S.

Vaxart shares skyrocket on news its COVID-19 vaccine candidate to be part of 'Operation Warp Speed'

OWS to Test First Oral COVID-19 Vaccine in Non-Human Primates OWS to Test First Oral COVID-19 Vaccine in Non-Human Primates

Vaxart’s COVID-19 Vaccine Selected for the U.S. Government’s Operation Warp Speed

Sorrento Therapeutics Inc

Investors are piling into coronavirus stocks as COVID-19 cases surge.

Why Vaxart, Inovio, and Sorrento Therapeutics Stocks Soared Today

Enabling Production of A Billion or More COVID-19 Vaccine Doses Per Year

Vaxart, Inc. Signs Memorandum of Understanding with Attwill Medical Solutions Sterilflow, LP

SOUTH SAN FRANCISCO, Calif., June  24, 2020  (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced today that it has joined the broad-market Russell 3000Ò Index at the conclusion of the 2020 Russell indexes annual reconstitution, effective Monday, June 29th 2020 after the U.S. market opening.

News for Vaxart Stock (VXRT)